Syncom Formulations AGM Approves Audited Financials, Dividend, and Director Appointments
Syncom Formulations' 38th AGM on Sept 30, 2026, approved audited FY26 financials and a 10% dividend (₹0.10/share). Key appointments confirmed include Mr. Rahul Vijay Bankda as MD and Mrs. Rinki Ankit Bankda as Whole-Time Director. Mr. Ank it Kedarmal Bankda was re-appointed, and Mrs. Ruchi Jindal as Woman Independent Director.
The dividend declaration and board appointments are material events for shareholders and stakeholders, impacting the company's governance and financial distribution.
The approval of audited financial statements, a dividend payout, and key director appointments at the AGM indicates positive corporate governance and financial health.
Syncom Formulations (India) Limited announced the outcome of its 38th Annual General Meeting (AGM), which was held virtually on Wednesday, September 30, 2026, from 2:00 P.M. to 2:42 P.M. IST.
During the AGM, members considered and approved several key resolutions. These included the adoption of the Audited Standalone and Consolidated Financial Statements for the Financial Year ended March 31, 2026. The approved financial statements encompass the Balance Sheet, Statement of Profit & Loss, Cash Flow, and Change in Equity, along with the reports of the Board of Directors and Auditors.
Furthermore, the members approved the declaration of a 10% dividend, amounting to ₹0.10 per equity share of face value ₹1 each, for the Financial Year ended March 31, 2026. The AGM also saw the approval of the appointment of Mr. Ank it Kedarmal Bankda, who retires by rotation, and his re-appointment. Additionally, the appointment of Mr. Rahul Vijay Bankda as a Director and subsequently as the Managing Director, along with his remuneration, was confirmed and approved. The appointment of Mrs. Rinki Ankit Bankda as a Director and Whole-Time Director, with her remuneration, also received confirmation and approval. The members also approved an increase in the remuneration payable to Mr. Ankur Vijay Bankda, the Chief Financial Officer. Lastly, the re-appointment of Mrs. Ruchi Jindal as a Woman Independent Director was confirmed.
The company has filed this outcome online with BSE Limited and the National Stock Exchange of India Limited.
What to do with a filing like this
Syncom Formulations (India) Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Syncom Formulations (India) Limited. Read the original for the full detail.